Cyclacel Pharmaceuticals Valuation
| CYCC Stock | USD 0.36 0.01 2.86% |
Cyclacel Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Cyclacel Pharmaceuticals from analyzing the firm fundamentals such as operating margin of (911.00) %, and Return On Equity of -5.71 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cyclacel Pharmaceuticals' valuation include:
Price Book 2.0157 | Enterprise Value -743.8 K | Enterprise Value Ebitda 0.0179 | Price Sales 27.978 | Enterprise Value Revenue 6.0999 |
Undervalued
Today
Please note that Cyclacel Pharmaceuticals' price fluctuation is very risky at this time. Calculation of the real value of Cyclacel Pharmaceuticals is based on 3 months time horizon. Increasing Cyclacel Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Cyclacel Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cyclacel Stock. However, Cyclacel Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.36 | Real 3.33 | Target 12.25 | Hype 0.38 | Naive 0.55 |
The real value of Cyclacel Stock, also known as its intrinsic value, is the underlying worth of Cyclacel Pharmaceuticals Company, which is reflected in its stock price. It is based on Cyclacel Pharmaceuticals' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Cyclacel Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Cyclacel Pharmaceuticals helps investors to forecast how Cyclacel stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cyclacel Pharmaceuticals more accurately as focusing exclusively on Cyclacel Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cyclacel Pharmaceuticals' intrinsic value based on its ongoing forecasts of Cyclacel Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cyclacel Pharmaceuticals' closest peers. If more than one evaluation category is relevant for Cyclacel Pharmaceuticals we suggest using both methods to arrive at a better estimate.
Cyclacel Pharmaceuticals Cash |
|
Cyclacel Valuation Trend
Comparing Cyclacel Pharmaceuticals' enterprise value against its market capitalization is a good way to estimate the value of Cyclacel Pharmaceuticals uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Cyclacel Pharmaceuticals Total Value Analysis
Cyclacel Pharmaceuticals is currently forecasted to have valuation of (743.76 K) with market capitalization of 2.24 M, debt of 37 K, and cash on hands of 29.08 M. The negative valuation of Cyclacel Pharmaceuticals may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Cyclacel Pharmaceuticals fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(743.76 K) | 2.24 M | 37 K | 29.08 M |
Cyclacel Pharmaceuticals Investor Information
About 18.0% of the company shares are held by institutions such as insurance companies. The book value of Cyclacel Pharmaceuticals was currently reported as 0.57. The company recorded a loss per share of 27.4. Cyclacel Pharmaceuticals last dividend was issued on the 15th of April 2020. The entity had 1:15 split on the 18th of December 2023. Based on the key indicators related to Cyclacel Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Cyclacel Pharmaceuticals is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Cyclacel Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cyclacel Pharmaceuticals has an asset utilization ratio of 4.77 percent. This indicates that the Company is making $0.0477 for each dollar of assets. An increasing asset utilization means that Cyclacel Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Cyclacel Pharmaceuticals Ownership Allocation
Cyclacel Pharmaceuticals shows 4.81 percent of its outstanding shares held by insiders and 18.02 percent owned by other corporate entities.Cyclacel Pharmaceuticals Profitability Analysis
The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Cyclacel Pharmaceuticals' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Cyclacel Pharmaceuticals and how it compares across the competition.
About Cyclacel Pharmaceuticals Valuation
The stock valuation mechanism determines Cyclacel Pharmaceuticals' current worth on a weekly basis. Our valuation model uses a comparative analysis of Cyclacel Pharmaceuticals. We calculate exposure to Cyclacel Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cyclacel Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 389 K | 408.4 K | |
| Pretax Profit Margin | (54.75) | (57.49) | |
| Operating Profit Margin | (54.54) | (57.27) | |
| Net Loss | (48.33) | (50.75) | |
| Gross Profit Margin | 0.83 | 0.88 |
Cyclacel Pharmaceuticals Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 850.8 K |
Cyclacel Pharmaceuticals Current Valuation Indicators
Valuation refers to the process of determining the present value of Cyclacel Pharmaceuticals and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Cyclacel we look at many different elements of the entity such as Cyclacel's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Cyclacel Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Cyclacel Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Cyclacel Pharmaceuticals' worth.Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |